Arrowhead Pharmaceuticals (ARWR) Financials

$14.42 +0.38 (+2.71%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$14.38 -0.04 (-0.31%)

As of 04:00 AM Eastern

Annual Income Statements for Arrowhead Pharmaceuticals

This table shows Arrowhead Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	9/30/2014	9/30/2015	9/30/2016	9/30/2017	9/30/2018	9/30/2019	9/30/2020	9/30/2021	9/30/2022	9/30/2023	9/30/2024
Net Income / (Loss) Attributable to Common Shareholders	-59	-92	-82	-34	-54	68	-85	-141	-176	-205	-599
Consolidated Net Income / (Loss)	-59	-92	-82	-34	-54	68	-85	-141	-176	-209	-610
Net Income / (Loss) Continuing Operations	-59	-92	-82	-34	-54	68	-85	-141	-176	-209	-610
Total Pre-Tax Income	-59	-92	-82	-34	-54	68	-85	-141	-173	-206	-612
Total Operating Income	-53	-96	-82	-37	-56	61	-93	-149	-179	-205	-601
Total Gross Profit	0.18	0.38	0.16	31	16	169	88	138	243	241	3.55
Total Revenue	0.18	0.38	0.16	31	16	169	88	138	243	241	3.55
Operating Revenue	0.18	0.38	0.16	31	16	169	88	138	243	241	3.55
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	53	96	82	68	72	108	181	287	422	446	605
Selling, General & Admin Expense	19	24	24	17	19	27	52	81	124	93	99
Research & Development Expense	23	57	62	51	53	81	129	206	297	353	506
Total Other Income / (Expense), net	-5.44	4.04	0.02	2.62	1.49	6.96	8.61	8.19	5.80	-1.49	-11
Interest Expense	-	-	-	-	-	-	-	0.00	0.00	18	32
Interest & Investment Income	0.57	0.73	0.27	0.42	1.05	6.96	9.19	6.12	5.03	15	23
Other Income / (Expense), net	-5.95	3.31	-0.24	2.20	0.44	0.00	-0.58	2.07	0.77	1.54	-1.75
Income Tax Expense	0.01	0.00	0.00	0.00	0.00	0.17	0.00	0.00	3.79	2.78	-2.77
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.10	-	-	-	-	-	0.00	0.00	-0.43	-4.00	-10
Basic Earnings per Share	($1.25)	($1.60)	($1.34)	($0.47)	($0.65)	$0.72	($0.84)	($1.36)	($1.67)	($1.92)	($5.00)
Weighted Average Basic Shares Outstanding	46.93M	57.36M	61.05M	73.90M	83.64M	93.86M	100.72M	103.75M	105.43M	106.75M	119.78M
Diluted Earnings per Share	($1.25)	($1.60)	($1.34)	($0.47)	($0.65)	$0.69	($0.84)	($1.36)	($1.67)	($1.92)	($5.00)
Weighted Average Diluted Shares Outstanding	46.93M	57.36M	61.05M	73.90M	83.64M	98.61M	100.72M	103.75M	105.43M	106.75M	119.78M
Weighted Average Basic & Diluted Shares Outstanding	46.93M	57.36M	61.05M	73.90M	83.64M	95.71M	102.76M	104.53M	106.01M	107.43M	124.43M

This table shows Arrowhead Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	6/30/2022	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-72	-86	-41	49	-103	-110	-133	-125	-171	-171	-173
Consolidated Net Income / (Loss)	-72	-86	-42	48	-104	-111	-135	-127	-174	-173	-175
Net Income / (Loss) Continuing Operations	-72	-86	-42	48	-104	-111	-135	-127	-174	-173	-175
Total Pre-Tax Income	-72	-82	-42	48	-103	-109	-139	-127	-174	-173	-175
Total Operating Income	-73	-84	-42	48	-103	-108	-137	-126	-176	-162	-161
Total Gross Profit	32	32	63	146	16	16	3.55	0.00	0.00	-	2.50
Total Revenue	32	32	63	146	16	16	3.55	0.00	0.00	-	2.50
Operating Revenue	32	32	63	146	16	16	3.55	0.00	0.00	-	2.50
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	105	115	105	98	119	124	140	126	176	162	164
Selling, General & Admin Expense	33	32	21	23	24	25	24	25	24	26	27
Research & Development Expense	72	83	84	75	95	100	116	101	152	136	137
Total Other Income / (Expense), net	0.86	1.67	0.34	-0.49	-0.68	-0.66	-2.14	-0.81	2.16	-11	-14
Interest Expense	0.00	-	2.85	5.06	5.16	5.26	5.37	7.24	5.09	15	22
Interest & Investment Income	1.24	1.58	2.68	4.56	4.17	3.89	2.80	6.25	6.50	7.17	7.60
Other Income / (Expense), net	-0.38	0.09	0.51	0.01	0.31	0.72	0.42	0.19	0.76	-3.12	0.34
Income Tax Expense	0.00	3.79	0.00	0.00	0.74	2.04	-3.31	0.00	0.00	0.55	0.10
Net Income / (Loss) Attributable to Noncontrolling Interest	0.00	-0.43	-0.49	-1.00	-1.18	-1.34	-2.51	-1.70	-3.18	-2.81	-2.13
Basic Earnings per Share	($0.68)	($0.81)	($0.39)	$0.46	($0.96)	($1.03)	($1.24)	($1.02)	($1.38)	($1.36)	($1.39)
Weighted Average Basic Shares Outstanding	105.75M	105.43M	106.04M	106.76M	107.00M	106.75M	107.42M	123.29M	124.20M	119.78M	124.85M
Diluted Earnings per Share	($0.68)	($0.80)	($0.39)	$0.45	($0.96)	($1.02)	($1.24)	($1.02)	($1.38)	($1.36)	($1.39)
Weighted Average Diluted Shares Outstanding	105.75M	105.43M	106.04M	108.14M	107.00M	106.75M	107.42M	123.29M	124.20M	119.78M	124.85M
Weighted Average Basic & Diluted Shares Outstanding	105.85M	106.01M	108.31M	106.90M	107.19M	107.43M	123.90M	124.20M	124.32M	124.43M	126.10M

This table details how cash moves in and out of Arrowhead Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	9/30/2014	9/30/2015	9/30/2016	9/30/2017	9/30/2018	9/30/2019	9/30/2020	9/30/2021	9/30/2022	9/30/2023	9/30/2024
Net Change in Cash & Equivalents	113	-51	4.15	-61	5.29	192	-79	41	-76	3.01	-12
Net Cash From Operating Activities	-35	-66	-64	-24	-47	173	-96	171	-136	-154	-463
Net Cash From Continuing Operating Activities	-35	-66	-64	-24	-47	173	-96	171	-136	-154	-463
Net Income / (Loss) Continuing Operations	-59	-92	-82	-34	-54	68	-85	-141	-176	-209	-610
Consolidated Net Income / (Loss)	-59	-92	-82	-34	-54	68	-85	-141	-176	-209	-610
Depreciation Expense	1.35	2.34	3.26	4.69	4.70	4.44	5.94	8.27	10	12	19
Amortization Expense	0.79	1.11	0.23	-0.04	0.38	1.07	0.53	0.27	2.91	-2.02	-3.24
Non-Cash Adjustments To Reconcile Net Income	7.84	20	14	7.89	8.45	12	44	78	139	143	109
Changes in Operating Assets and Liabilities, net	13	2.43	0.16	-2.10	-6.31	87	-62	225	-112	-98	23
Net Cash From Investing Activities	-36	14	13	-49	-7.43	-48	-241	-142	-5.42	-96	-420
Net Cash From Continuing Investing Activities	-36	14	13	-49	-7.43	-48	-241	-142	-5.42	-96	-420
Purchase of Property, Plant & Equipment	-1.72	-12	-3.86	-7.92	-1.42	-12	-12	-24	-53	-177	-141
Purchase of Investments	-46	0.00	0.00	-45	-52	-90	-279	-241	-223	-246	-721
Sale and/or Maturity of Investments	12	26	17	4.25	46	55	50	123	271	327	442
Net Cash From Financing Activities	185	0.29	55	12	60	66	258	11	65	253	871
Net Cash From Continuing Financing Activities	185	0.29	55	12	60	66	258	11	65	253	871
Repayment of Debt	-0.23	-0.21	-0.22	-0.20	-0.21	-2.42	-	-	0.00	0.00	-3.13
Issuance of Debt	-	-	-	-	-	-	-	-	0.00	0.00	392
Issuance of Common Equity	173	0.00	52	12	57	61	250	-	0.00	0.00	429
Other Financing Activities, net	13	0.50	3.12	-0.17	3.58	8.28	7.47	11	65	253	52
Cash Income Taxes Paid	0.01	0.00	0.00	0.00	-0.00	-0.30	0.10	-0.00	-0.00	0.00	-3.74

This table details how cash moves in and out of Arrowhead Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	6/30/2022	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	53	-31	94	-67	-30	5.40	-53	69	-58	29	-49
Net Cash From Operating Activities	-69	-69	-76	-32	-21	-26	-118	-92	-115	-137	-146
Net Cash From Continuing Operating Activities	-69	-69	-76	-32	-21	-26	-118	-92	-115	-137	-146
Net Income / (Loss) Continuing Operations	-72	-86	-42	48	-104	-111	-135	-127	-174	-173	-175
Consolidated Net Income / (Loss)	-72	-86	-42	48	-104	-111	-135	-127	-174	-173	-175
Depreciation Expense	2.59	2.66	2.69	2.67	3.28	3.86	4.26	4.53	4.78	5.03	5.24
Amortization Expense	1.68	0.90	0.69	-0.77	-0.95	-0.99	-0.84	1.73	6.99	-11	-5.70
Non-Cash Adjustments To Reconcile Net Income	39	41	23	26	26	68	29	26	22	33	36
Changes in Operating Assets and Liabilities, net	-40	-28	-60	-108	55	14	-15	2.75	25	9.59	-6.31
Net Cash From Investing Activities	61	36	-81	-36	-9.91	31	65	-269	6.95	-223	77
Net Cash From Continuing Investing Activities	61	36	-81	-36	-9.91	31	65	-269	6.95	-223	77
Purchase of Property, Plant & Equipment	-9.54	-33	-39	-27	-47	-64	-69	-34	-14	-24	-7.52
Purchase of Investments	-75	-	-111	-81	-41	-12	0.00	-310	-119	-292	-34
Sale and/or Maturity of Investments	146	69	69	73	78	107	133	75	140	94	118
Net Cash From Financing Activities	61	0.86	251	0.52	1.14	0.82	0.27	431	50	389	21
Net Cash From Continuing Financing Activities	61	0.86	251	0.52	1.14	0.82	0.27	431	50	389	21
Repayment of Debt	-	-	-	-	-	-	0.00	-	-	-	-5.00
Issuance of Common Equity	-	-	-	-	-	-	0.00	-	-	-	25
Other Financing Activities, net	61	0.86	251	0.52	1.14	0.82	0.27	1.51	50	0.22	0.63
Cash Income Taxes Paid	-	-0.00	0.00	-	-	-	-1.00	-2.02	-0.05	-0.68	-0.01

This table presents Arrowhead Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	9/30/2014	9/30/2015	9/30/2016	9/30/2017	9/30/2018	9/30/2019	9/30/2020	9/30/2021	9/30/2022	9/30/2023	9/30/2024
Total Assets	183	132	128	104	112	350	523	710	692	766	1,140
Total Current Assets	155	103	91	68	79	265	322	385	405	416	695
Cash & Equivalents	133	81	85	25	30	222	144	184	108	111	103
Short-Term Investments	22	18	0.00	41	46	37	172	183	268	293	578
Accounts Receivable	-	0.00	0.08	0.07	0.33	0.66	0.85	10	1.41	-	0.00
Prepaid Expenses	0.59	3.29	1.29	0.87	1.27	3.32	4.25	4.36	7.29	8.81	9.54
Other Current Assets	0.05	0.82	3.77	1.36	0.64	2.56	1.78	2.19	20	4.03	4.97
Plant, Property, & Equipment, net	3.87	4.53	15	16	14	23	31	49	110	290	386
Total Noncurrent Assets	24	25	22	21	19	61	169	277	176	59	58
Intangible Assets	1.01	25	22	20	19	17	15	14	12	10	8.56
Other Noncurrent Operating Assets	0.04	0.05	0.12	0.14	0.14	0.14	16	18	59	49	50
Total Liabilities & Shareholders' Equity	183	132	128	104	112	350	523	710	692	766	1,140
Total Liabilities	17	23	33	23	16	106	61	301	274	478	949
Total Current Liabilities	12	16	26	19	12	97	41	147	139	105	103
Short-Term Debt	0.26	0.22	0.19	0.21	0.22	-	-	-	-	-	0.00
Accounts Payable	2.58	5.03	12	4.08	2.81	7.65	6.83	9.46	2.87	36	11
Accrued Expenses	1.40	5.38	4.59	4.56	5.04	6.50	5.39	14	47	40	63
Current Employee Benefit Liabilities	3.27	3.82	3.97	3.40	3.94	4.96	8.06	9.77	12	18	22
Other Current Liabilities	4.23	1.35	1.65	0.74	0.05	0.02	1.11	2.25	2.78	11	6.77
Total Noncurrent Liabilities	4.98	6.75	7.51	4.45	4.00	8.74	20	155	135	373	846
Long-Term Debt	-	0.00	2.53	2.33	2.10	-	-	-	-	0.00	393
Capital Lease Obligations	0.76	0.54	-	-	-	-	-	-	-	105	111
Other Noncurrent Operating Liabilities	4.23	6.06	0.20	0.20	0.20	0.00	20	23	79	268	341
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	166	110	95	81	95	244	462	409	418	287	191
Total Preferred & Common Equity	167	110	96	81	96	245	462	409	399	271	185
Total Common Equity	167	110	96	81	96	245	462	409	399	271	185
Common Stock	391	427	494	514	583	664	966	1,054	1,219	1,301	1,806
Retained Earnings	-225	-317	-398	-433	-487	-419	-504	-645	-821	-1,026	-1,626
Accumulated Other Comprehensive Income / (Loss)	0.00	-0.14	0.01	0.03	-0.02	-0.39	0.02	-0.07	-0.14	-3.22	4.75
Noncontrolling Interest	-0.56	-0.56	-0.56	-0.56	-0.56	-0.56	-	0.00	20	16	5.62

This table presents Arrowhead Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	6/30/2022	12/31/2022	3/31/2023	6/30/2023	12/31/2023	3/31/2024	6/30/2024	12/31/2024
Total Assets	752	891	891	796	626	955	884	1,014
Total Current Assets	432	575	575	470	238	542	450	571
Cash & Equivalents	139	202	135	105	58	128	69	54
Short-Term Investments	277	300	346	346	162	395	367	499
Accounts Receivable	0.24	40	69	1.25	-	-	-	2.50
Prepaid Expenses	6.76	8.41	9.94	10	11	11	9.21	9.37
Other Current Assets	8.89	25	14	7.16	7.10	7.51	4.18	5.74
Plant, Property, & Equipment, net	72	147	185	231	333	359	376	387
Total Noncurrent Assets	247	169	131	94	55	54	58	56
Intangible Assets	12	12	11	11	9.84	9.41	8.99	8.14
Other Noncurrent Operating Assets	69	42	41	41	45	45	49	48
Total Liabilities & Shareholders' Equity	752	891	891	796	626	955	884	1,014
Total Liabilities	278	495	426	414	453	460	545	958
Total Current Liabilities	128	122	87	70	64	65	97	94
Short-Term Debt	-	-	-	-	-	-	-	1.63
Accounts Payable	5.89	0.80	9.56	7.87	4.46	8.52	27	14
Accrued Expenses	32	48	40	38	47	37	48	59
Current Employee Benefit Liabilities	2.65	4.09	5.49	4.43	8.78	14	16	11
Other Current Liabilities	2.88	2.66	2.71	2.82	3.88	5.86	6.47	7.00
Total Noncurrent Liabilities	149	373	339	344	389	395	448	864
Long-Term Debt	-	-	-	-	-	-	-	408
Capital Lease Obligations	-	79	80	80	115	114	112	109
Other Noncurrent Operating Liabilities	78	253	258	264	274	281	336	347
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	474	396	465	382	174	495	339	56
Total Preferred & Common Equity	454	377	447	365	160	484	331	53
Total Common Equity	454	377	447	365	160	484	331	53
Common Stock	1,189	1,239	1,261	1,282	1,321	1,769	1,787	1,847
Retained Earnings	-735	-862	-813	-916	-1,159	-1,284	-1,455	-1,799
Accumulated Other Comprehensive Income / (Loss)	-0.14	-0.26	-0.33	-0.41	-1.26	-1.10	-0.99	4.14
Noncontrolling Interest	20	19	18	17	13	12	8.43	3.49

This table displays calculated financial ratios and metrics derived from Arrowhead Pharmaceuticals' official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	9/30/2014	9/30/2015	9/30/2016	9/30/2017	9/30/2018	9/30/2019	9/30/2020	9/30/2021	9/30/2022	9/30/2023	9/30/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-39.71%	118.29%	-58.55%	19,736.49%	-48.60%	945.67%	-47.87%	57.16%	75.89%	-1.03%	-98.52%
EBITDA Growth	-96.29%	-56.29%	12.02%	61.59%	-67.23%	232.30%	-230.85%	-58.62%	-18.77%	-17.38%	-204.41%
EBIT Growth	-91.28%	-56.46%	11.53%	57.56%	-59.51%	210.26%	-253.20%	-56.78%	-20.94%	-14.47%	-196.28%
NOPAT Growth	-116.66%	-80.14%	14.83%	54.74%	-51.20%	255.88%	-206.84%	-59.98%	-19.77%	-14.84%	-193.21%
Net Income Growth	-85.23%	-56.56%	11.11%	57.93%	-58.38%	224.84%	-224.39%	-66.58%	-25.31%	-18.57%	-191.34%
EPS Growth	3.85%	-28.00%	16.25%	64.93%	-38.30%	206.15%	-221.74%	-61.90%	-22.79%	-14.97%	-160.42%
Operating Cash Flow Growth	-86.08%	-85.53%	1.95%	62.84%	-97.27%	466.42%	-155.37%	278.82%	-179.46%	-13.05%	-200.77%
Free Cash Flow Firm Growth	-277.58%	-208.60%	34.89%	46.01%	-35.43%	432.37%	-194.28%	182.07%	-343.58%	26.36%	-128.52%
Invested Capital Growth	-466.60%	213.48%	6.54%	43.66%	18.21%	-379.77%	114.95%	-2,424.83%	68.75%	81.45%	220.72%
Revenue Q/Q Growth	0.00%	0.00%	-7.32%	38.21%	18.68%	23.43%	-28.84%	28.48%	-2.68%	-6.04%	-81.93%
EBITDA Q/Q Growth	-18.48%	-2.15%	3.03%	28.08%	-1.01%	46.75%	-221.92%	-10.22%	-12.52%	-14.58%	-12.80%
EBIT Q/Q Growth	-18.17%	-2.49%	3.08%	24.67%	-0.51%	51.52%	-180.66%	-10.38%	-12.13%	-13.29%	-10.59%
NOPAT Q/Q Growth	-36.88%	-3.09%	4.04%	23.78%	-1.67%	51.15%	-178.91%	-10.99%	-11.88%	-13.57%	-9.85%
Net Income Q/Q Growth	-17.22%	-2.58%	3.00%	25.05%	-0.05%	49.37%	-246.32%	-11.87%	-14.66%	-13.61%	-11.39%
EPS Q/Q Growth	-30.21%	1.84%	4.29%	29.85%	5.80%	46.81%	-236.00%	-10.57%	-12.84%	-12.94%	-7.30%
Operating Cash Flow Q/Q Growth	-18.49%	-1.70%	2.77%	3.92%	12.14%	10.53%	-35.44%	-6.94%	-48.90%	21.76%	-31.66%
Free Cash Flow Firm Q/Q Growth	-24.79%	-2.72%	-0.33%	4.75%	10.76%	3.50%	-9.63%	-23.12%	-25.72%	3.19%	-3.95%
Invested Capital Q/Q Growth	-545.95%	-41.69%	-31.58%	4.74%	-19.06%	15.68%	-68.60%	1.56%	40.94%	63.59%	-0.22%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-32,621.89%	-23,356.26%	-49,575.55%	-95.98%	-312.31%	39.51%	-99.19%	-100.11%	-67.59%	-80.17%	-16,543.99%
Operating Margin	-30,443.59%	-25,124.08%	-51,627.09%	-117.79%	-346.52%	36.25%	-105.87%	-107.77%	-73.39%	-85.16%	-16,927.06%
EBIT Margin	-33,844.49%	-24,258.54%	-51,780.99%	-110.78%	-343.80%	36.25%	-106.53%	-106.28%	-73.08%	-84.52%	-16,976.29%
Profit (Net Income) Margin	-33,557.38%	-24,068.29%	-51,614.64%	-109.46%	-337.32%	40.27%	-96.09%	-101.85%	-72.56%	-86.93%	-17,169.61%
Tax Burden Percent	100.01%	100.00%	100.00%	100.01%	100.00%	99.74%	100.00%	100.00%	102.19%	101.35%	99.55%
Interest Burden Percent	99.14%	99.21%	99.68%	98.81%	98.11%	111.37%	90.20%	95.84%	97.17%	101.49%	101.60%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.26%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-9,727.21%	-476.61%	-171.63%	-201.70%	0.00%	0.00%	0.00%	0.00%	0.00%	-34,263.52%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-9,709.16%	-449.48%	-159.98%	-179.42%	0.00%	0.00%	0.00%	0.00%	0.00%	-34,184.09%
Return on Net Nonoperating Assets (RNNOA)	0.00%	9,660.50%	396.74%	132.54%	139.86%	0.00%	0.00%	0.00%	0.00%	0.00%	34,008.54%
Return on Equity (ROE)	-61.26%	-66.72%	-79.87%	-39.09%	-61.84%	40.07%	-23.96%	-32.36%	-42.67%	-59.33%	-254.98%
Cash Return on Invested Capital (CROIC)	0.00%	-765.99%	-482.94%	-207.46%	-218.39%	0.00%	-1,509.88%	0.00%	0.00%	0.00%	-3,122.72%
Operating Return on Assets (OROA)	-53.81%	-58.82%	-62.96%	-29.97%	-51.47%	26.52%	-21.49%	-23.85%	-25.35%	-27.92%	-63.28%
Return on Assets (ROA)	-53.35%	-58.36%	-62.76%	-29.61%	-50.50%	29.46%	-19.39%	-22.85%	-25.18%	-28.72%	-64.00%
Return on Common Equity (ROCE)	-62.00%	-66.99%	-80.30%	-39.34%	-62.23%	40.20%	-23.98%	-32.36%	-41.65%	-56.33%	-243.55%
Return on Equity Simple (ROE_SIMPLE)	-35.26%	-83.45%	-85.50%	-42.22%	-56.84%	27.79%	-18.31%	-34.45%	-44.29%	-77.13%	-328.77%
Net Operating Profit after Tax (NOPAT)	-37	-67	-57	-26	-39	61	-65	-104	-125	-144	-421
NOPAT Margin	-21,310.51%	-17,586.85%	-36,138.97%	-82.45%	-242.56%	36.16%	-74.11%	-75.44%	-51.37%	-59.61%	-11,848.94%
Net Nonoperating Expense Percent (NNEP)	-21.04%	-18.06%	-27.13%	-11.64%	-22.28%	3.68%	-5.12%	-6.85%	-9.41%	-16.84%	-79.42%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	10,699.06%	6,409.74%	14,902.07%	55.72%	118.38%	15.73%	59.41%	58.56%	51.16%	38.44%	2,781.22%
R&D to Revenue	13,221.74%	15,028.83%	39,232.39%	162.08%	328.13%	48.02%	146.46%	149.21%	122.23%	146.71%	14,245.85%
Operating Expenses to Revenue	30,543.59%	25,224.08%	51,727.09%	217.79%	446.52%	63.75%	205.87%	207.77%	173.39%	185.16%	17,027.06%
Earnings before Interest and Taxes (EBIT)	-59	-93	-82	-35	-55	61	-94	-147	-178	-203	-603
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-57	-89	-78	-30	-50	67	-87	-138	-164	-193	-587
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.69	3.11	4.67	3.98	17.61	10.98	9.54	15.92	8.78	10.61	12.99
Price to Tangible Book Value (P/TBV)	4.72	4.02	6.08	5.31	21.91	11.80	9.87	16.47	9.05	11.03	13.61
Price to Revenue (P/Rev)	4,465.48	897.19	2,820.10	10.31	104.53	15.91	50.06	47.07	14.38	11.96	678.12
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	39.51	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	2.53%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	21.00	29.33	14.62	76.67	0.00	449.11	0.00	0.00	0.00	156.29
Enterprise Value to Revenue (EV/Rev)	3,455.28	639.20	2,294.66	8.28	99.90	14.11	44.91	42.63	12.48	10.79	629.92
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	35.71	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	38.93	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	39.03	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	13.77	0.00	34.41	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	16.91	0.00	54.07	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.01	0.01	0.03	0.03	0.02	0.00	0.00	0.00	0.00	0.36	2.64
Long-Term Debt to Equity	0.00	0.00	0.03	0.03	0.02	0.00	0.00	0.00	0.00	0.36	2.64
Financial Leverage	-1.06	-1.00	-0.88	-0.83	-0.78	-1.11	-1.07	-1.22	-1.32	-1.11	-0.99
Leverage Ratio	1.15	1.14	1.27	1.32	1.22	1.36	1.24	1.42	1.70	2.07	3.98
Compound Leverage Factor	1.14	1.13	1.27	1.30	1.20	1.51	1.11	1.36	1.65	2.10	4.05
Debt to Total Capital	0.61%	0.69%	2.79%	3.04%	2.38%	0.00%	0.00%	0.00%	0.00%	26.70%	72.52%
Short-Term Debt to Total Capital	0.16%	0.20%	0.20%	0.25%	0.23%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.45%	0.49%	2.59%	2.79%	2.15%	0.00%	0.00%	0.00%	0.00%	26.70%	72.52%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-0.33%	-0.50%	-0.57%	-0.67%	-0.57%	-0.23%	0.00%	0.00%	4.74%	4.04%	0.81%
Common Equity to Total Capital	99.72%	99.82%	97.78%	97.63%	98.19%	100.23%	100.00%	100.00%	95.26%	69.26%	26.67%
Debt to EBITDA	-0.02	-0.01	-0.03	-0.08	-0.05	0.00	0.00	0.00	0.00	-0.54	-0.86
Net Debt to EBITDA	3.09	1.10	1.05	2.09	1.47	0.00	0.00	0.00	0.00	1.55	0.30
Long-Term Debt to EBITDA	-0.01	-0.01	-0.03	-0.08	-0.04	0.00	0.00	0.00	0.00	-0.54	-0.86
Debt to NOPAT	-0.03	-0.01	-0.05	-0.10	-0.06	0.00	0.00	0.00	0.00	-0.73	-1.20
Net Debt to NOPAT	4.73	1.46	1.44	2.44	1.90	0.00	0.00	0.00	0.00	2.08	0.42
Long-Term Debt to NOPAT	-0.02	-0.01	-0.04	-0.09	-0.05	0.00	0.00	0.00	0.00	-0.73	-1.20
Altman Z-Score	26.01	4.21	2.23	2.33	54.96	15.19	42.39	11.60	5.98	1.66	-1.59
Noncontrolling Interest Sharing Ratio	-1.21%	-0.40%	-0.54%	-0.63%	-0.63%	-0.33%	-0.08%	0.00%	2.40%	5.05%	4.48%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	13.07	6.47	3.53	3.63	6.37	2.73	7.92	2.62	2.92	3.95	6.74
Quick Ratio	13.01	6.21	3.33	3.51	6.22	2.67	7.78	2.58	2.72	3.83	6.60
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-29	-89	-58	-31	-42	141	-133	109	-266	-196	-447
Operating Cash Flow to CapEx	-2,074.33%	-548.93%	-1,669.00%	-302.33%	-3,322.66%	1,441.84%	-801.55%	726.91%	-257.94%	-87.07%	-327.17%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-10.67	-13.81
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-8.40	-14.31
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-18.04	-18.68
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.27	0.15	0.73	0.20	0.22	0.35	0.33	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	439.89	81.70	341.44	116.75	24.91	41.70	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.05	0.09	0.02	2.03	1.10	9.09	3.25	3.48	3.06	1.20	0.01
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.83	4.47	1.07	3.13	14.65	8.75	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.83	4.47	1.07	3.13	14.65	8.75	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-10	12	12	18	21	-59	8.80	-205	-64	-12	14
Invested Capital Turnover	-0.03	0.55	0.01	2.08	0.83	-8.93	-3.52	-1.41	-1.81	-6.35	2.89
Increase / (Decrease) in Invested Capital	-8.44	22	0.76	5.41	3.24	-80	68	-213	141	52	26
Enterprise Value (EV)	605	244	363	260	1,613	2,382	3,952	5,896	3,036	2,597	2,237
Market Capitalization	781	343	447	324	1,687	2,686	4,405	6,509	3,498	2,880	2,408
Book Value per Share	$3.15	$1.85	$1.57	$1.09	$1.09	$2.57	$4.51	$3.92	$3.77	$2.53	$1.49
Tangible Book Value per Share	$3.13	$1.43	$1.21	$0.82	$0.88	$2.39	$4.36	$3.79	$3.65	$2.44	$1.42
Total Capital	167	110	98	83	98	244	462	409	418	392	695
Total Debt	1.02	0.76	2.73	2.53	2.33	0.00	0.00	0.00	0.00	105	504
Total Long-Term Debt	0.76	0.54	2.53	2.33	2.10	0.00	0.00	0.00	0.00	105	504
Net Debt	-176	-98	-83	-63	-74	-303	-453	-613	-482	-299	-177
Capital Expenditures (CapEx)	1.71	12	3.86	7.92	1.42	12	12	24	53	177	141
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-11	-12	-20	-16	-9.91	-91	-34	-130	-110	-93	-89
Debt-free Net Working Capital (DFNWC)	143	87	65	49	67	168	282	238	266	311	592
Net Working Capital (NWC)	143	87	65	49	66	168	282	238	266	311	592
Net Nonoperating Expense (NNE)	21	25	25	8.48	15	-6.94	19	37	52	66	189
Net Nonoperating Obligations (NNO)	-176	-98	-83	-63	-74	-303	-453	-613	-482	-299	-177
Total Depreciation and Amortization (D&A)	2.14	3.45	3.49	4.65	5.08	5.51	6.47	8.53	13	10	15
Debt-free, Cash-free Net Working Capital to Revenue	-6,254.80%	-3,027.78%	-12,829.54%	-51.57%	-61.37%	-53.63%	-38.42%	-93.81%	-45.20%	-38.47%	-2,496.71%
Debt-free Net Working Capital to Revenue	81,838.71%	22,824.12%	41,086.23%	157.32%	412.75%	99.63%	320.13%	172.15%	109.55%	129.19%	16,679.89%
Net Working Capital to Revenue	81,687.85%	22,767.17%	40,963.51%	156.66%	411.36%	99.63%	320.13%	172.15%	109.55%	129.19%	16,679.89%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.25)	($1.60)	($1.34)	($0.47)	($0.65)	$0.72	($0.84)	($1.36)	($1.67)	($1.92)	($5.00)
Adjusted Weighted Average Basic Shares Outstanding	54.68M	59.55M	74.17M	74.83M	92.22M	93.86M	100.72M	103.75M	105.43M	106.75M	119.78M
Adjusted Diluted Earnings per Share	($1.25)	($1.60)	($1.34)	($0.47)	($0.65)	$0.69	($0.84)	($1.36)	($1.67)	($1.92)	($5.00)
Adjusted Weighted Average Diluted Shares Outstanding	54.68M	59.55M	74.17M	74.83M	92.22M	98.61M	100.72M	103.75M	105.43M	106.75M	119.78M
Adjusted Basic & Diluted Earnings per Share	($1.25)	($1.60)	($1.34)	($0.47)	($0.65)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	46.93M	57.36M	61.05M	73.90M	83.64M	95.71M	102.76M	104.53M	106.01M	107.43M	124.43M
Normalized Net Operating Profit after Tax (NOPAT)	-34	-66	-60	-26	-39	61	-65	-104	-125	-144	-421
Normalized NOPAT Margin	-19,467.75%	-17,240.24%	-37,824.12%	-82.45%	-242.56%	36.16%	-74.11%	-75.44%	-51.37%	-59.61%	-11,848.94%
Pre Tax Income Margin	-33,554.35%	-24,067.67%	-51,613.12%	-109.46%	-337.30%	40.37%	-96.09%	-101.85%	-71.01%	-85.78%	-17,247.54%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-11.10	-18.63
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-7.83	-13.01
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-20.75	-23.01
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-17.47	-17.38
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Arrowhead Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	6/30/2022	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-29.37%	-17.52%	127.95%	-3.65%	-51.18%	-49.02%	-94.32%	-100.00%	-100.00%	0.00%	-29.60%
EBITDA Growth	-135.86%	-29.56%	38.04%	7.64%	-45.01%	-30.63%	-246.94%	-339.16%	-63.50%	-63.67%	-21.74%
EBIT Growth	-134.86%	-29.79%	34.99%	11.22%	-39.72%	-28.51%	-227.01%	-361.56%	-71.28%	-53.63%	-18.33%
NOPAT Growth	-128.78%	-29.20%	33.46%	15.91%	-40.86%	-29.23%	-224.07%	-283.40%	-71.51%	-49.73%	-18.21%
Net Income Growth	-140.76%	-35.61%	33.50%	7.46%	-44.53%	-29.17%	-223.78%	-366.37%	-67.08%	-56.14%	-29.43%
EPS Growth	-134.48%	-31.15%	35.00%	9.76%	-41.18%	-27.50%	-217.95%	-326.67%	-43.75%	-33.33%	-12.10%
Operating Cash Flow Growth	-132.40%	-186.06%	-23.17%	-150.49%	69.81%	62.28%	-56.05%	-191.68%	-455.51%	-429.26%	-24.13%
Free Cash Flow Firm Growth	-170.53%	-218.68%	-137.18%	-533.22%	2.01%	35.83%	-386.57%	-113.73%	-15.34%	-9.23%	78.35%
Invested Capital Growth	47.91%	68.75%	19.06%	90.30%	69.91%	81.45%	148.39%	685.99%	144.04%	220.72%	-68.15%
Revenue Q/Q Growth	-78.65%	-2.58%	98.09%	133.86%	-89.18%	1.72%	-77.94%	-100.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-248.36%	-16.19%	52.30%	230.91%	-299.86%	-4.67%	-26.69%	9.76%	-36.63%	-4.78%	5.77%
EBIT Q/Q Growth	-269.20%	-14.26%	50.29%	215.73%	-312.56%	-5.09%	-26.49%	7.44%	-39.19%	5.74%	2.57%
NOPAT Q/Q Growth	-222.82%	-14.98%	49.74%	263.31%	-249.26%	-5.48%	-26.05%	7.58%	-39.58%	7.91%	0.49%
Net Income Q/Q Growth	-262.39%	-19.29%	51.35%	214.03%	-318.40%	-6.62%	-21.94%	6.19%	-36.99%	0.36%	-1.08%
EPS Q/Q Growth	-265.85%	-17.65%	51.25%	215.38%	-313.33%	-6.25%	-21.57%	17.74%	-35.29%	1.45%	-2.21%
Operating Cash Flow Q/Q Growth	-209.70%	0.11%	-9.86%	58.06%	34.40%	-24.78%	-354.52%	21.61%	-24.94%	-18.89%	-6.60%
Free Cash Flow Firm Q/Q Growth	-978.84%	-32.35%	68.45%	-40.58%	-66.95%	13.32%	-139.19%	38.25%	9.91%	17.92%	52.58%
Invested Capital Q/Q Growth	28.42%	40.94%	-121.75%	89.66%	-122.09%	63.59%	678.54%	25.27%	-83.31%	-0.22%	52.67%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	0.00%	0.00%	100.00%
EBITDA Margin	-212.91%	-253.94%	-61.15%	34.23%	-632.35%	-650.69%	-3,736.86%	0.00%	0.00%	0.00%	-6,461.60%
Operating Margin	-224.94%	-265.49%	-67.36%	32.93%	-648.99%	-672.98%	-3,845.25%	0.00%	0.00%	0.00%	-6,456.48%
EBIT Margin	-226.11%	-265.21%	-66.55%	32.94%	-647.06%	-668.53%	-3,833.40%	0.00%	0.00%	0.00%	-6,442.84%
Profit (Net Income) Margin	-222.28%	-272.18%	-66.85%	32.60%	-657.98%	-689.66%	-3,812.33%	0.00%	0.00%	0.00%	-7,008.72%
Tax Burden Percent	100.00%	104.61%	100.04%	100.00%	100.72%	101.86%	97.61%	100.00%	100.00%	100.32%	100.06%
Interest Burden Percent	98.31%	98.11%	100.40%	98.97%	100.96%	101.28%	101.88%	100.79%	99.20%	104.52%	108.72%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-249.86%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-160.54%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	97.35%
Return on Equity (ROE)	-33.79%	-42.67%	-40.43%	-33.17%	-43.03%	-59.33%	-106.24%	0.00%	-151.84%	0.00%	-152.50%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-612.23%	-503.04%	-2,997.65%	-3,122.72%	-865.57%
Operating Return on Assets (OROA)	-76.02%	-92.02%	-24.21%	11.27%	-214.24%	-220.84%	-918.03%	0.00%	0.00%	0.00%	-19.64%
Return on Assets (ROA)	-74.74%	-94.44%	-24.32%	11.15%	-217.86%	-227.82%	-912.99%	0.00%	0.00%	0.00%	-21.37%
Return on Common Equity (ROCE)	-33.04%	-41.65%	-39.41%	-32.50%	-41.15%	-56.33%	-100.16%	0.00%	-146.46%	0.00%	-141.36%
Return on Equity Simple (ROE_SIMPLE)	-33.91%	0.00%	-41.22%	-34.05%	-50.49%	0.00%	-188.79%	-98.70%	-165.59%	0.00%	-1,235.12%
Net Operating Profit after Tax (NOPAT)	-51	-59	-29	48	-72	-76	-96	-88	-123	-114	-113
NOPAT Margin	-157.46%	-185.85%	-47.16%	32.93%	-454.29%	-471.09%	-2,691.68%	0.00%	0.00%	0.00%	-4,519.54%
Net Nonoperating Expense Percent (NNEP)	-3.42%	-4.98%	-2.27%	-0.09%	-6.47%	-9.01%	-12.37%	-8.70%	-13.71%	-25.14%	-89.32%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-33.09%	-	-	-	-19.66%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	102.25%	101.43%	33.55%	15.88%	150.21%	152.65%	664.74%	0.00%	0.00%	0.00%	1,076.40%
R&D to Revenue	222.70%	264.06%	133.81%	51.19%	598.78%	620.33%	3,280.51%	0.00%	0.00%	0.00%	5,480.08%
Operating Expenses to Revenue	324.94%	365.49%	167.36%	67.07%	748.99%	772.98%	3,945.25%	0.00%	0.00%	0.00%	6,556.48%
Earnings before Interest and Taxes (EBIT)	-73	-84	-42	48	-102	-108	-136	-126	-175	-165	-161
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-69	-80	-38	50	-100	-105	-133	-120	-164	-171	-162
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	8.20	8.78	11.40	6.16	10.45	10.61	20.45	7.32	9.77	12.99	44.48
Price to Tangible Book Value (P/TBV)	8.43	9.05	11.76	6.31	10.76	11.03	21.78	7.47	10.04	13.61	52.63
Price to Revenue (P/Rev)	14.90	14.38	15.45	10.08	14.88	11.96	18.05	99.89	164.29	678.12	935.75
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	46.48	36.61	203.01	156.29	105.66
Enterprise Value to Revenue (EV/Rev)	12.65	12.48	13.58	8.39	13.33	10.79	17.54	88.68	148.20	629.92	923.45
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.20	0.17	0.21	0.36	0.66	0.23	0.33	2.64	9.25
Long-Term Debt to Equity	0.00	0.00	0.20	0.17	0.21	0.36	0.66	0.23	0.33	2.64	9.22
Financial Leverage	-1.35	-1.32	-1.41	-1.18	-1.16	-1.11	-1.13	-0.93	-1.03	-0.99	-0.61
Leverage Ratio	1.63	1.70	1.99	1.74	1.81	2.07	2.66	1.92	2.33	3.98	7.14
Compound Leverage Factor	1.60	1.66	2.00	1.72	1.83	2.09	2.71	1.94	2.31	4.16	7.76
Debt to Total Capital	0.00%	0.00%	16.70%	14.69%	17.30%	26.70%	39.86%	18.66%	24.84%	72.52%	90.24%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.28%
Long-Term Debt to Total Capital	0.00%	0.00%	16.70%	14.69%	17.30%	26.70%	39.86%	18.66%	24.84%	72.52%	89.96%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	4.27%	4.74%	4.06%	3.36%	3.71%	4.04%	4.61%	1.91%	1.87%	0.81%	0.61%
Common Equity to Total Capital	95.73%	95.26%	79.24%	81.95%	78.99%	69.26%	55.53%	79.44%	73.29%	26.67%	9.15%
Debt to EBITDA	0.00	0.00	-0.56	-0.58	-0.47	-0.54	-0.40	-0.25	-0.22	-0.86	-0.84
Net Debt to EBITDA	0.00	0.00	3.82	3.49	2.46	1.55	0.37	0.90	0.62	0.30	0.06
Long-Term Debt to EBITDA	0.00	0.00	-0.56	-0.58	-0.47	-0.54	-0.40	-0.25	-0.22	-0.86	-0.84
Debt to NOPAT	0.00	0.00	-0.72	-0.76	-0.63	-0.73	-0.55	-0.34	-0.29	-1.20	-1.18
Net Debt to NOPAT	0.00	0.00	4.89	4.55	3.28	2.08	0.50	1.23	0.85	0.42	0.08
Long-Term Debt to NOPAT	0.00	0.00	-0.72	-0.76	-0.63	-0.73	-0.55	-0.34	-0.29	-1.20	-1.18
Altman Z-Score	7.17	6.43	4.62	3.74	4.41	2.07	1.66	2.94	1.10	-0.33	-0.98
Noncontrolling Interest Sharing Ratio	2.22%	2.40%	2.51%	2.00%	4.37%	5.05%	5.73%	0.00%	3.55%	0.00%	7.31%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.37	2.92	4.71	6.60	6.69	3.95	3.73	8.31	4.65	6.74	6.09
Quick Ratio	3.25	2.72	4.44	6.32	6.45	3.83	3.46	8.03	4.52	6.60	5.92
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-151	-199	-63	-88	-148	-128	-306	-189	-170	-140	-66
Operating Cash Flow to CapEx	-721.63%	-210.13%	-194.07%	-115.95%	-44.58%	-40.57%	-171.64%	-271.10%	-798.80%	-564.93%	-1,946.14%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-22.07	-17.48	-28.61	-24.31	-57.00	-26.08	-33.41	-9.54	-3.06
Operating Cash Flow to Interest Expense	0.00	0.00	-26.51	-6.26	-4.03	-4.93	-21.96	-12.75	-22.66	-9.37	-6.76
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-40.16	-11.66	-13.06	-17.07	-34.75	-17.46	-25.49	-11.03	-7.10
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.34	0.35	0.36	0.34	0.33	0.33	0.24	0.04	0.02	0.00	0.00
Accounts Receivable Turnover	549.31	41.70	14.02	7.71	344.84	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	4.18	3.06	2.79	2.27	1.69	1.20	0.76	0.13	0.06	0.01	0.01
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.66	8.75	26.04	47.33	1.06	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.66	8.75	26.04	47.33	1.06	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-108	-64	-142	-15	-33	-12	69	86	14	14	22
Invested Capital Turnover	-1.58	-1.81	-1.76	-3.29	-3.64	-6.35	-4.97	1.00	-2.16	2.89	0.06
Increase / (Decrease) in Invested Capital	100	141	33	137	76	52	210	101	47	26	-47
Enterprise Value (EV)	3,161	3,036	3,781	2,290	3,415	2,597	3,188	3,146	2,912	2,237	2,309
Market Capitalization	3,723	3,498	4,300	2,751	3,812	2,880	3,280	3,543	3,228	2,408	2,339
Book Value per Share	$4.29	$3.77	$3.56	$4.12	$3.41	$2.53	$1.49	$3.90	$2.66	$1.49	$0.42
Tangible Book Value per Share	$4.18	$3.65	$3.45	$4.02	$3.31	$2.44	$1.40	$3.83	$2.59	$1.42	$0.36
Total Capital	474	418	476	545	462	392	289	609	451	695	575
Total Debt	0.00	0.00	79	80	80	105	115	114	112	504	519
Total Long-Term Debt	0.00	0.00	79	80	80	105	115	114	112	504	517
Net Debt	-582	-482	-538	-480	-415	-299	-105	-409	-325	-177	-34
Capital Expenditures (CapEx)	9.54	33	39	27	47	64	69	34	14	24	7.52
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-112	-110	-49	6.65	-52	-93	-46	-47	-83	-89	-75
Debt-free Net Working Capital (DFNWC)	304	266	453	488	400	311	174	476	353	592	478
Net Working Capital (NWC)	304	266	453	488	400	311	174	476	353	592	477
Net Nonoperating Expense (NNE)	21	27	12	0.49	32	35	40	39	51	60	62
Net Nonoperating Obligations (NNO)	-582	-482	-538	-480	-415	-299	-105	-409	-325	-177	-34
Total Depreciation and Amortization (D&A)	4.28	3.56	3.38	1.90	2.33	2.87	3.43	6.26	12	-6.11	-0.47
Debt-free, Cash-free Net Working Capital to Revenue	-44.94%	-45.20%	-17.55%	2.44%	-20.20%	-38.47%	-25.37%	-131.48%	-424.08%	-2,496.71%	-2,981.28%
Debt-free Net Working Capital to Revenue	121.70%	109.55%	162.75%	178.76%	156.10%	129.19%	95.84%	1,343.20%	1,798.39%	16,679.89%	19,136.12%
Net Working Capital to Revenue	121.70%	109.55%	162.75%	178.76%	156.10%	129.19%	95.84%	1,343.20%	1,798.39%	16,679.89%	19,071.12%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.68)	($0.81)	($0.39)	$0.46	($0.96)	($1.03)	($1.24)	($1.02)	($1.38)	($1.36)	($1.39)
Adjusted Weighted Average Basic Shares Outstanding	105.75M	105.43M	106.04M	106.76M	107.00M	106.75M	107.42M	123.29M	124.20M	119.78M	124.85M
Adjusted Diluted Earnings per Share	($0.68)	($0.80)	($0.39)	$0.45	($0.96)	($1.02)	($1.24)	($1.02)	($1.38)	($1.36)	($1.39)
Adjusted Weighted Average Diluted Shares Outstanding	105.75M	105.43M	106.04M	108.14M	107.00M	106.75M	107.42M	123.29M	124.20M	119.78M	124.85M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	105.85M	106.01M	108.31M	106.90M	107.19M	107.43M	123.90M	124.20M	124.32M	124.43M	126.10M
Normalized Net Operating Profit after Tax (NOPAT)	-51	-59	-29	34	-72	-76	-96	-88	-123	-114	-113
Normalized NOPAT Margin	-157.46%	-185.85%	-47.16%	23.05%	-454.29%	-471.09%	-2,691.68%	0.00%	0.00%	0.00%	-4,519.54%
Pre Tax Income Margin	-222.28%	-260.20%	-66.82%	32.60%	-653.29%	-677.08%	-3,905.63%	0.00%	0.00%	0.00%	-7,004.60%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-14.61	9.53	-19.85	-20.45	-25.36	-17.39	-34.43	-11.29	-7.44
NOPAT to Interest Expense	0.00	0.00	-10.35	9.52	-13.94	-14.41	-17.81	-12.19	-24.20	-7.75	-5.22
EBIT Less CapEx to Interest Expense	0.00	0.00	-28.27	4.12	-28.89	-32.60	-38.16	-22.10	-37.27	-12.95	-7.79
NOPAT Less CapEx to Interest Expense	0.00	0.00	-24.01	4.12	-22.97	-26.56	-30.60	-16.90	-27.04	-9.41	-5.57
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Arrowhead Pharmaceuticals' Financials

When does Arrowhead Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Arrowhead Pharmaceuticals' fiscal year ends in September. Their fiscal year 2024 ended on September 30, 2024.

How has Arrowhead Pharmaceuticals' net income changed over the last 10 years?

Arrowhead Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$609.69 million in 2024, rising from -$58.73 million in 2014. The previous period was -$209.28 million in 2023. Check out Arrowhead Pharmaceuticals' forecast to explore projected trends and price targets.

What is Arrowhead Pharmaceuticals's operating income?

Arrowhead Pharmaceuticals's total operating income in 2024 was -$601.08 million, based on the following breakdown:

Total Gross Profit: $3.55 million
Total Operating Expenses: $604.63 million

How has Arrowhead Pharmaceuticals revenue changed over the last 10 years?

Over the last 10 years, Arrowhead Pharmaceuticals' total revenue changed from $175 thousand in 2014 to $3.55 million in 2024, a change of 1,929.1%.

How much debt does Arrowhead Pharmaceuticals have?

Arrowhead Pharmaceuticals' total liabilities were at $948.74 million at the end of 2024, a 98.3% increase from 2023, and a 5,536.7% increase since 2014.

How much cash does Arrowhead Pharmaceuticals have?

In the past 10 years, Arrowhead Pharmaceuticals' cash and equivalents has ranged from $24.84 million in 2017 to $221.80 million in 2019, and is currently $102.69 million as of their latest financial filing in 2024.

How has Arrowhead Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, Arrowhead Pharmaceuticals' book value per share changed from 3.15 in 2014 to 1.49 in 2024, a change of -52.6%.

Related Companies

This page (NASDAQ:ARWR) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arrowhead Pharmaceuticals (ARWR) Financials

Frequently Asked Questions About Arrowhead Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arrowhead Pharmaceuticals (ARWR) Financials

Annual Income Statements for Arrowhead Pharmaceuticals

Quarterly Income Statements for Arrowhead Pharmaceuticals

Annual Cash Flow Statements for Arrowhead Pharmaceuticals

Quarterly Cash Flow Statements for Arrowhead Pharmaceuticals

Annual Balance Sheets for Arrowhead Pharmaceuticals

Quarterly Balance Sheets for Arrowhead Pharmaceuticals

Annual Metrics and Ratios for Arrowhead Pharmaceuticals

Quarterly Metrics and Ratios for Arrowhead Pharmaceuticals

Frequently Asked Questions About Arrowhead Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools